

# R&D PORTFOLIO December 2021

	DISCOVERY			TRANSLATION			DEVELOPMENT		IMPLEMENTATION
	Screen	Hit-to-lead	Lead optimization	Pre-clinical	Phase I	Phase IIa/ Proof-of-concept	Phase IIb/III	Registration	Treatment access
SLEEPING SICKNESS							Acoziborole + Fexinidazole for <i>T.b. rhodesiense</i> +		Fexinidazole for <i>T.b. gambiense</i> * + Nifurtimox-eflornithine combination therapy (NECT)*
LEISHMANIASIS	Screening	Leishmaniasis Hit-to-lead	S07 series +	DNDI-6174 +	DNDI-6148 +	LXE408 Novartis +	New CL combination	New VL treatments (Latin America) New treatments for HIV/VL	SSG&PM (East Africa)* New VL treatments (South Asia)*
		NTD Drug Discovery Booster Hit-to-lead	CF series +		DNDI-0690 +		New treatments for PKDL		
					GSK899 DDD853651 +		Miltefosine + paromomycin combination (Africa)		
					CpG-D35 for CL + GSK245 DDD1305143 +				
CHAGAS DISEASE	Screening	Chagas disease Hit-to-lead	UW series +	Biomarkers	DNDI-6148 +	Fexinidazole +	New benznidazole regimens +		Benznidazole paediatric dosage forms*
		NTD Drug Discovery Booster Hit-to-lead	Daiichi Sankyo series +						
FILARIA: RIVER BLINDNESS				CC6166 +	Oxfendazole +	Emodepside + TylAMac (ABBV-4083) +			
							Fosravuconazole +		
MYCETOMA									
HIV					5 FC (cryptococcal meningitis)			4-in-1 (ABC/3TC/LPV/r)	Super-booster for children with HIV/TB* 2-in-1 LPV/r pellets 5FC, LAmB access (crypto meningitis)
HEPATITIS C							Ravidasvir + sofosbuvir +		Ravidasvir* and other DAAs +
COVID-19/ Pandemic preparedness		Broad-spectrum antivirals Hit-to-lead	TMEM16 series Moonshot	Pre-clinical support			ANTICOV		
MALARIA ★									Fixed-dose combination ASMQ* Fixed-dose combination ASAQ*

★ Implementation transferred to the Medicines for Malaria Venture in 2015

+ NCE (New chemical entity)

\* Treatments delivered by DNDi with Partners

▶ Treatments not delivered by DNDi, but DNDi working on access